Reporter brief
Metformin has extensive preclinical evidence but limited clinical proof of geroprotective effects in systematic review.
What happened
This systematic review examined pharmacological interventions targeting aging pathways, including metformin, from literature published January 2010–May 2026. Metformin and rapamycin had among the most extensive preclinical and translational evidence, but the review found that clinical evidence for broadly applicable geroprotection remains limited. The authors emphasize a substantial gap between mechanistic plausibility and clinically validated geroprotection in humans.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Systematic review; Mixed.
Aging populations and those with chronic diseases (cardiovascular diseases, cancer, diabetes, neurodegenerative disorders)
- Design
- Systematic review
- Sample
- —
- Journal
- International journal of molecular sciences
- Published
- Aug 22, 2026
Effect size
Not reported with specific metrics; qualitatively assessed across studies
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Metformin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.